Elranatamab under FDA priority review for hard-to-treat myeloma
The U.S. Food and Drug Administration (FDA) has granted priority review to Pfizer‘s application of its investigational under-the-skin therapy elranatamab for people with relapsed or refractory multiple myeloma. Priority review is given to therapies that target serious medical conditions that outperform current treatments to make them available to…